EMLI: Phase-I and II trials of the malaria pre-erithrocytic vaccine LSA-3 and refinement of measurable outcomes

• Research unit: EU RFP
• Project number: 00.0556

Key words (English)

Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects

Alternative project number (English)

EU project number: QLK2-CT-2001-01886

Research programs (English)

EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases

Short description (English)

See abstract

Abstract (English)

This proposal is based on a decade of European-sponsored research which led to the rational identification, characterization and demonstration of protection in Chimpanzees by LSA3. It aims at testing, in phase-I and conditional phase-II trials, the protective effect demonstrated in the primate genetically 98,4% similar to humans. Besides safety and immunogenicity, it includes a unique approach to the understanding of critical mechanism of defence in the liver, aimed at improving surrogates to guide future vaccine development. Three novel vaccine delivery systems will be used: Lactococcus lactis recombinant protein in the new SBAS2 adjuvant from SB Bio, DKA immunisation with the Aventis Pasteur licensed Vical vector, lipopeptide immunisation without adjuvant, yet another recent European discovery. It is performed which the expert guidance of he 2 leading vaccine industries.

References in databases (English)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 00.0556